CROI 2022 TB Round Up
Treatment Action Group welcomes the tuberculosis (TB) data reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI). This is a summary of major findings — and TAG’s take on them.
European Commitments to TB R&D Investments: Promises Made to Be Broken?
In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.
2021 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis
After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.
Landmark TB Trials Results Published in New England Journal of Medicine
Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24
A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...